CRVS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRVS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-05-12), Corvus Pharmaceuticals's share price is $4.055. Corvus Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.42. Hence, Corvus Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Corvus Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:
Corvus Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2024 was $-0.12. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.42.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 21.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 21.70% per year.
During the past 11 years, Corvus Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 25.00% per year. The lowest was -32.90% per year. And the median was 19.50% per year.
The historical data trend for Corvus Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corvus Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Corvus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Corvus Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Corvus Pharmaceuticals's Price-to-Free-Cash-Flow falls into.
Corvus Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 4.055 | / | -0.416 | |
= | N/A |
Corvus Pharmaceuticals's Share Price of today is $4.055.
Corvus Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.42.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Corvus Pharmaceuticals (NAS:CRVS) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
William Benton Jones | officer: See Remarks | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Miller Richard A Md | director, officer: President and CEO | PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521 |
Linda S Grais | director | 86 ALEJANDRA AVE, ATHERTON CA 94027 |
Leiv Lea | officer: Chief Financial Officer | PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521 |
Ecor1 Capital, Llc | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Peter A. Thompson | director, 10 percent owner | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Edith P. Mitchell | director | 1640 MARENGO ST., LOS ANGELES CA 90033 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Mehrdad Mobasher | officer: Chief Medical Officer | 863 MITTEN ROAD, BURLINGAME CA 94010 |
Adams Street Partners Llc | 10 percent owner | ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807 |
Terry P Gould | director, 10 percent owner | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Joseph J Buggy | officer: EVP Discovery Research | CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Daniel W. Hunt | officer: SVP, Chief Business Officer | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Erik J. Verner | officer: V.P., Chemistry Research | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
From GuruFocus
By GuruFocus News • 11-13-2024
By Marketwired • 11-12-2024
By Marketwired • 07-31-2024
By GlobeNewswire • 11-09-2024
By GuruFocus News • 03-26-2025
By Marketwired • 02-04-2025
By GuruFocus News • 04-09-2025
By Marketwired • 09-03-2024
By GuruFocus News • 03-25-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.